New data support early use of newer DMTs in children with RRMS, say specialists

New study data on the use of newer versus injectable disease modifying therapies (DMTs) in children with relapsing-remitting multiple sclerosis (RRMS) have led to calls for a shift in practice.

Dr Omar Abdel-Mannan from Great Ormond Street Hospital in London, UK, said the improved outcomes seen with the use of newer DMTs add to the evidence supporting their first-line use in pediatric MS.

Presenting at the ICNA/CNS 2020 virtual conference, Dr Abdel-Mannan reported findings from a real-world observational study involving 7 centers in the UK, and a total of 103 patients with a diagnosis of RRMS who were treated with DMTs between 2012 and 2018.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.